Table 5.
Individual risk predictor performance
| All N = 990 |
CBD stone ( +) n = 197 |
CBD stone ( −) n = 793 |
p value | |
|---|---|---|---|---|
| Very strong predictor | ||||
| CBD stones on CT/AUS | 135 (13.64%) | 115 (58.97%) | 20 (2.52%) | < 0.001* |
| Strong predictor | ||||
| CBD > 6 mm | 160 (16.16%) | 114 (58.16%) | 46 (5.79%) | < 0.001* |
| Total bilirubin > 4 mg/dL | 37 (3.7%) | 34 (17.35%) | 3 (0.04%) | < 0.001* |
| Bilirubin 1.8–4 mg/dL | 112 (11.31%) | 63 (31.63%) | 49 (6.17%) | < 0.001* |
| Moderate predictor | ||||
| Abnormal liver biochemistry data | 349 (35.25%) | 157 (80.10%) | 192 (24.18%) | < 0.001* |
| Age > 55 years | 486 (49.09%) | 109 (55.61%) | 377 (47.48%) | 0.168 |
| Clinical gallstone pancreatitis | 33 (3.33%) | 30 (15.31%) | 3 (0.38%) | < 0.001* |
*Statistically significant (p < 0.05)